Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 8/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159415 | 1.00 | HCAR3 (0.66) | HCAR3POLBMAPTRAB9AMEN1 | |
| SCHEMBL599138 | 0.80 | HCAR3 (1.00) | HCAR3POLBMAPTRAB9AMEN1 | |
| SCHEMBL30159507 | 0.76 | CA12 (0.43) | MAPTRAB9AMEN1KMT2AHPGD | |
| SCHEMBL24849978 | 0.76 | CA12 (0.43) | MAPTRAB9AMEN1KMT2AHPGD | |
| SCHEMBL29687311 | 0.74 | RAB9A (0.52) | POLBMAPTRAB9AMEN1KMT2A | |
| SCHEMBL15532201 | 0.72 | HCAR3 (0.48) | HCAR3POLBMAPTHPGDALDH1A1 | |
| SCHEMBL1256199 | 0.71 | HCAR3 (0.76) | HCAR3POLBMAPTRAB9AMEN1 | |
| SCHEMBL12369468 | 0.71 | HCAR3 (0.76) | HCAR3POLBMAPTRAB9AMEN1 | |
| SCHEMBL4246208 | 0.71 | ALDH1A1 (0.56) | POLBMAPTMEN1KMT2AHPGD | |
| SCHEMBL23091676 | 0.70 | CA12 (0.57) | RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | HCAR3 1608/4885POLB 3091/4885MAPT 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.